Moderna (MRNA) Thoughts Post Science Day - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating and $68.00 price target on Moderna (NASDAQ: MRNA) after Science Day ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE